keyword
MENU ▼
Read by QxMD icon Read
search

drug coated balloon angioplasty

keyword
https://www.readbyqxmd.com/read/28185166/paclitaxel-coated-balloon-for-femoropopliteal-artery-disease
#1
REVIEW
Saurabh Mehrotra, Ganesh Paramasivam, Sundeep Mishra
PURPOSE OF THE REVIEW: Percutaneous transluminal angioplasty is an established form of therapy for femoropopliteal artery disease. Currently, percutaneous transluminal angioplasty (PTA) is carried out using standard balloon with or without deployment of a stent but is associated with a high rate of restenosis and stent-related complications. Treatment options for restenosis, especially in-stent restenosis, are limited. Drug-coated balloons promise to reduce the rates of restenosis by effective delivery of antiproliferative agent (paclitaxel) directly to vessel wall without the need for a permanent implant...
February 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28169215/drug-coated-balloon-angioplasty-for-in-stent-restenosis-of-femoropopliteal-arteries-a-meta-analysis
#2
Salvatore Cassese, Gjin Ndrepepa, Sebastian Kufner, Robert A Byrne, Daniele Giacoppo, Ilka Ott, Karl-Ludwig Laugwitz, Heribert Schunkert, Adnan Kastrati, Massimiliano Fusaro
AIMS: To perform a meta-analysis investigating the outcomes of patients undergoing percutaneous revascularization with drug-coated balloon (DCB) angioplasty because of femoropopliteal in-stent restenosis (ISR). METHODS AND RESULTS: We searched scientific databases for studies of DCB angioplasty for femoropopliteal ISR. The primary outcome was target lesion revascularization (TLR). The main secondary outcome was recurrent ISR. Other outcomes of interest were Rutherford class (RC) improvement, ankle-brachial index (ABI) and death...
February 7, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28162988/drug-coated-balloon-angioplasty-for-subclavian-artery-stenosis-a-potential-novel-indication
#3
Derar Albashaireh, Georges Khoueiry, Owen Mogabgab, Qusay Saleh, Michael Foster, Nidal Abi Rafeh
Subclavian artery stenosis is associated with increased cardiovascular disease mortality. It remains an important treatable cause of upper extremity, brain and cardiac ischemia. Endovascular treatment with angioplasty and stenting has become the preferred modality of treatment. Surgical revascularization is reserved for difficult cases with unfavorable anatomy to endovascular approach. Here we describe a case of subclavian artery stenosis causing subclavian steal syndrome with unfavorable anatomy to stenting treated successfully with drug coated balloon angioplasty with maintenance of patency at 6months...
January 23, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28134126/changes-in-high-sensitivity-troponin-after-drug-coated-balloon-angioplasty-for-drug-eluting-stent-restenosis
#4
Roisin Colleran, Yukinora Harada, Sebastian Kufner, Daniele Giacoppo, Michael Joner, Salvatore Cassese, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Robert A Byrne
AIMS: Success of drug-coated balloon therapy might be compromised by intraprocedural particulate embolization of matrix coating, which may cause downstream microvascular obstruction. We aimed to investigate whether drug-coated balloon therapy was associated with an increase in markers of myocardial necrosis compared with drug-eluting stents or plain balloon angioplasty. METHODS AND RESULTS: In the ISAR DESIRE 3 trial, patients with limus-eluting stent restenosis were randomized to treatment with a paclitaxel-coated balloon (PCB), paclitaxel-eluting stent (PES) or balloon angioplasty (BA)...
January 31, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28133467/application-of-drug-coated-balloon-in-coronary-artery-intervention-challenges-and-opportunities
#5
REVIEW
Lei Gao, Yun-Dai Chen
In recent decades, the outcomes of coronary heart disease (CHD) have markedly improved, which can be partly attributed to the use of novel drugs (especially statins and antiplatelet drugs) and partly to the evolution of percutaneous coronary intervention (PCI). From percutaneous transluminal coronary angioplasty to bare-metal stent and then to drug-eluting stent, every step of PCI is attractive to interventional cardiologist, great progress has been made for patients with CHD. In the past few years, some successor devices for treating CHD have emerged...
November 2016: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/28126182/paclitaxel-coated-balloon-reduces-target-lesion-revascularization-compared-with-standard-balloon-angioplasty
#6
REVIEW
Nicholas Candy, Eugene Ng, Ramesh Velu
OBJECTIVE: Peripheral arterial disease (PAD) is a highly prevalent condition that contributes significantly to the morbidity and mortality of affected patients. PAD creates a significant economic burden on health care systems around the world. We reviewed all available literature to provide a meta-analysis assessing the outcome of patients treated with drug-eluting balloons (DEBs) compared with percutaneous transluminal balloon angioplasty (PTA) through measuring the rate of target lesion revascularization (TLR)...
February 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/28116914/treatment-of-coronary-artery-in-stent-restenosis
#7
Damianos G Kokkinidis, Stephen W Waldo, Ehrin J Armstrong
Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices...
January 31, 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/28111411/serial-observations-of-in-stent-restenosis-treated-with-drug-coated-balloon-angioplasty-by-optical-coherence-tomography-and-coronary-angioscopy
#8
Nobuhiro Murata, Tadateru Takayama, Takafumi Hiro
The drug-coated balloon (DCB) is a device that is used to reduce the risk of stent re-implantation in patients with in-stent restenosis (ISR). However, imaging findings of the drug covering the neointimal plaque immediately after treatment of ISR by DCB, and during follow-up, have only been discussed in a few reports. Herein, we describe the use of optical coherence tomography (OCT) and angioscopy to evaluate ISR before and after treatment with DCB, and during the follow-up period in 3 patients. The patients developed critical ISR during the follow-up period after drug-eluting stent (DES) implantation...
February 7, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28089147/sequent-please-vs-pantera-lux-drug-coated-balloon-angioplasty-in-real-life-results-from-the-d%C3%A3-sseldorf-dcb-registry
#9
Athena Assadi-Schmidt, Annemarie Mohring, Eva Liebsch, Lisa Dannenberg, Alina Achilles, Martin Pöhl, Shazia Afzal, Verena Veulemans, Patrick Horn, Roberto Sansone, Florian Bönner, Bodo Levkau, Malte Kelm, Tobias Zeus, Amin Polzin
BACKGROUND: In-stent restenosis (ISR) is still a major concern in interventional cardiology. Drug coated balloon (DCB) angioplasty has been shown to be a promising option in treatment of ISR. However heterogeneity of different DCBs in suppression of neointimal growth has been described in a porcine model of coronary ISR. Therefore, in this registry analysis, we compared two frequently used paclitaxel eluting DCBs, the SeQuent Please and the Pantera Lux DCB. METHODS: 571 patients were treated with DCB angioplasty at the Heinrich-Heine University Düsseldorf between 2009 and 2012...
March 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28008792/directional-atherectomy-with-antirestenotic-therapy-vs-drug-coated-balloon-angioplasty-alone-for-isolated-popliteal-artery-lesions
#10
Konstantinos Stavroulakis, Arne Schwindt, Giovanni Torsello, Arne Stachmann, Christiane Hericks, Michel J Bosiers, Efthymios Beropoulis, Stefan Stahlhoff, Theodosios Bisdas
PURPOSE: To report a single-center study comparing drug-coated balloon (DCB) angioplasty vs directional atherectomy with antirestenotic therapy (DAART) for isolated lesions of the popliteal artery. METHODS: Seventy-two patients were treated with either DCB angioplasty alone (n=31) or with DAART (n=41) for isolated popliteal artery stenotic disease between October 2009 and December 2015. The majority of patients presented with lifestyle-limiting claudication (74% vs 86%, respectively)...
December 1, 2016: Journal of Endovascular Therapy
https://www.readbyqxmd.com/read/27973329/a-novel-constrained-paclitaxel-coated-angioplasty-balloon-catheter
#11
Bodo Cremers, Gary Binyamin, Yvonne P Clever, Paul Seifert, Eitan Konstantino, Bettina Kelsch, Stephanie Bienek, Ulrich Speck, Bruno Scheller
AIMS: The study assessed drug adherence, transfer to the vessel wall, tolerance and efficacy of a constrained angioplasty balloon (Chocolate™) coated with an excipient enhanced paclitaxel coating (CCB) in the porcine model. METHODS AND RESULTS: Drug adherence was investigated in vitro. Drug transfer was evaluated in porcine arteries. A stent overstretch model was chosen to provoke intimal thickening in the efficacy and tolerance study. Conventional uncoated balloons were used as controls...
December 15, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27916742/angiographic-and-clinical-outcomes-of-patients-treated-with-drug-coated-balloon-angioplasty-for-in-stent-restenosis-after-coronary-bifurcation-stenting-with-a-two-stent-technique
#12
Yukinori Harada, Roisin Colleran, Susanne Pinieck, Daniele Giacoppo, Jonathan Michel, Sebastian Kufner, Salvatore Cassese, Michael Joner, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Robert A Byrne
AIMS: We conducted this study to evaluate the efficacy of drug-coated balloon therapy for in-stent restenosis after coronary bifurcation stenting. METHODS AND RESULTS: Patients who underwent angioplasty with at least one paclitaxel-coated balloon for in-stent restenosis after bifurcation intervention using a two-stent approach were included. Two types of paclitaxel-coated balloon were used, with either iopromid (iopromide-PCB) or butyryltri-n-hexyl citrate excipient (BTHC-PCB)...
December 6, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27894569/five-year-outcomes-after-paclitaxel-coated-balloon-angioplasty-for-drug-eluting-stent-restenosis
#13
Katsuya Miura, Kazushige Kadota, Seiji Habara, Takenobu Shimada, Masanobu Ohya, Hidewo Amano, Shunsuke Kubo, Yusuke Hyodo, Suguru Otsuru, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto
The long-term outcomes of patients who underwent paclitaxel-coated balloon (PCB) angioplasty for drug-eluting stent restenosis (DES-ISR) remain unclear. We investigated the 5-year safety and efficacy outcomes of PCB angioplasty for DES-ISR. The study included 185 patients with 216 DES-ISR lesions who underwent PCB angioplasty from September 2008 to December 2010. Two serial angiographic follow-ups were routinely scheduled at 6 and 18 months after the index procedure. Five-year clinical outcomes were investigated...
February 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/27884360/cost-effectiveness-of-endovascular-femoropopliteal-intervention-using-drug-coated-balloons%C3%A2-versus-standard-percutaneous-transluminal-angioplasty-results-from-the-in-pact%C3%A2-sfa-ii-trial
#14
Adam C Salisbury, Haiyan Li, Katherine R Vilain, Michael R Jaff, Peter A Schneider, John R Laird, David J Cohen
OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness of drug-coated balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA). BACKGROUND: Recent trials have reported lower rates of target lesion revascularization with DCB angioplasty versus standard PTA. However, the cost-effectiveness of DCB angioplasty is unknown. METHODS: A prospective economic study was performed alongside the IN.PACT SFA II (IN...
November 28, 2016: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/27881352/-efficacy-and-safety-of-drug-coated-balloon-angioplasty-in-treatment-of-lower-extremity-arterial-occlusive-disease-a-meta-analysis-of-11-trials
#15
Kun Ran, Chao Wang, Yu Zhao, Zhi Xiang
OBJECTIVE: To evaluate the efficacy and safety of drug-coated balloon (DCB) angioplasty versus uncoated balloon (UCB) angioplasty in treatment of lower extremity arterial occlusive disease (LEAOD). METHODS: Randomized controlled trial comparing DCB and UCB angioplasty for treatment of LEAOD were searched in online databases. Literature screening and quality assessment was carried out according to the established inclusion criteria and exclusion criteria. Restenosis rate at 6 months after surgery, late lumen loss, target lesion revascularization rate, patency rate, mortality rate, and amputation rate at 1 year after operation were compared between DCB group and UCB group using RevMan 5...
November 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27879111/modelling-chemistry-and-biology-after-implantation-of-a-drug-eluting-stent-part-i-drug-transport
#16
Tuoi Vo, William Lee, Adam Peddle, Martin Meere
Drug-eluting stents have been used widely to prevent restenosis of arteries following percutaneous balloon angioplasty. Mathematical modelling plays an important role in optimising the design of these stents to maximise their efficiency. When designing a drug-eluting stent system, we expect to have a sufficient amount of drug being released into the artery wall for a sufficient period to prevent restenosis. In this paper, a simple model is considered to provide an elementary description of drug release into artery tissue from an implanted stent...
April 1, 2017: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/27869561/successful-drug-coated-balloon-angioplasty-and-single-anti-platelet-therapy-to-treat-an-ischaemic-stroke-patient-with-haemorrhage-and-acute-coronary-syndrome
#17
Hee Hwa Ho, Kwang How Mok
A 55-year-old male presented with two challenging problems, i.e. acute coronary syndrome (ACS) and a major bleeding episode. He first presented with ischaemic stroke and was treated with thrombolysis. However this was complicated by haemorrhagic transformation. He subsequently developed ACS with urgent coronary angiography demonstrating a critical stenosis in the proximal left anterior descending artery. Percutaneous coronary intervention (PCI) was deemed necessary but we were mindful of causing bleeding complications from the use of anti-thrombotic therapy...
March 2016: Acute Cardiac Care
https://www.readbyqxmd.com/read/27867580/understanding-and-managing-in-stent-restenosis-a-review-of-clinical-data-from-pathogenesis-to-treatment
#18
REVIEW
Dario Buccheri, Davide Piraino, Giuseppe Andolina, Bernardo Cortese
The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known as "restenosis". This phenomenon is due to vessel remodeling/recoil in case of no-stent strategy or, in case of stent employ, "neointimal proliferation" that consists in an excessive tissue proliferation in the luminal surface of the stent otherwise by a further new-occurring atherosclerotic process called "neoatherosclerosis". The exact incidence of in-stent restenosis (ISR) is not easy to determine caused by different clinical, angiographic and operative factors...
October 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27865639/a-network-meta-analysis-of-randomized-controlled-trials-comparing-treatment-modalities-for-de-novo-superficial-femoral-artery-occlusive-lesions
#19
REVIEW
Constantine N Antonopoulos, Spyridon N Mylonas, Konstantinos G Moulakakis, Theodoros N Sergentanis, George S Sfyroeras, Andreas M Lazaris, John D Kakisis, Spyros N Vasdekis
BACKGROUND: Treatment of superficial femoral artery (SFA) lesions remains challenging. We conducted a network meta-analysis of randomized controlled trials aiming to explore the efficacy of treatment modalities for SFA "de novo" lesions. METHODS: Eleven treatments for SFA occlusive disease were recognized. We used primary patency and binary restenosis at 12-month follow-up as proxies of efficacy for the treatment of SFA lesions. RESULTS: A total of 33 studies (66 study arms; 4659 patients) were deemed eligible...
January 2017: Journal of Vascular Surgery
https://www.readbyqxmd.com/read/27858114/safety-of-bailout-stenting-after-paclitaxel-coated-balloon-angioplasty
#20
K H Mok, U Wickramarachchi, T Watson, H H Ho, S Eccleshall, P J L Ong
BACKGROUND: Bailout stenting after suboptimal paclitaxel-coated balloon (PCB) angioplasty is required in up to 28% of cases. We sought to compare the safety of bailout stenting with drug-eluting stents (DES) compared with the more established combination of PCB with bare metal stents (BMS). METHODS: We retrospectively evaluated all patients who had stents implanted owing to suboptimal PCB angioplasty results between January 2010 and April 2015. Endpoints analyzed were major adverse cardiac events (MACE) - defined as cardiovascular death, nonfatal myocardial infarction (MI), and target lesion revascularization (TLR) - as well as major and minor bleeding...
November 17, 2016: Herz
keyword
keyword
102043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"